 teniposid continu infus cytosin arabinosid initi induct failur childhood acut lymphoblast leukemia pediatr oncolog group pilot studi twenty-six evalu children acut lymphoblast leukemia all initi remiss drug period continu infus cytosin arabinosid ara-c twenty-two day ara-c continu infus day second shorten cours day patient evid antileukem effect abl second cours last patient daili dose infus ara-c daili dosag twelv complet remiss CR all trend respons rate number drug initi induct regimen CR patient prior two-drug induct attempt CR patient prior three- four-drug induct attempt CR patient prior five- seven-drug induct attempt non-t-cel patient t-cell patient remiss median time complet remiss initi treatment day rang day period cours induct cours day median day median toxic signific due aplasia infect patient sever hypotens patient remiss marrow transplant due parent request patient median remiss durat month rang month patient marrow entir group patient patient aliv long-term event-fre survivor allogen marrow transplant due current use aggress initi induct regimen poor prognosi children initi remiss intens regimen continu therapi altern therapi bone marrow transplant